During Wednesday’s current trade, Lockheed Martin Corporation (NYSE:LMT)’s shares gained 0.77%, to $192.21.
Following successful completion of on-orbit testing, the U.S. Navy accepted the third Lockheed Martin (LMT)-built Mobile User Objective System (MUOS) satellite.
Launched January 20, MUOS-3 is the latest addition to a network of orbiting satellites and relay ground stations that is revolutionizing secure communications for mobile military forces. Users with operational MUOS terminals can seamlessly connect around the globe, beyond line-of-sight, with new smart phone-like capabilities, counting simultaneous and crystal-clear voice, video and mission data, on a high-speed Internet Protocol-based system.
The MUOS network is predictable to provide near global coverage before year end. MUOS-1 and MUOS-2, launched respectively in 2012 and 2013, are already operational and providing high-quality voice communications. Lockheed Martin handed over the last of four required ground stations to the Navy in February. MUOS-4 is predictable to launch later this year.
Lockheed Martin Corporation, a security and aerospace company, engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It also provides administration, engineering, technical, scientific, logistics, and information services. Its Aeronautics segment offers combat and air mobility aircraft, unmanned air vehicles, and related technologies.
NiSource Inc. (NYSE:NI)’s shares dropped -0.62% to $46.23, during the current trading session Wednesday’s, hitting its highest level.
Columbia Pipeline Group, Inc. (CPG) declared that Lester P. Silverman has joined its board of directors in anticipation of CPG’s separation from NiSource Inc. (NI), which is predictable to take place on July 1, 2015.
Mr. Silverman joins current NiSource Inc. board members that have been elected to serve on CPG’s board of directors. They comprise: Sigmund L. Cornelius, Marty R. Kittrell, W. Lee Nutter, Deborah S. Parker, Teresa A. Taylor and Mr. Skaggs.
Mr. Silverman is a Director Emeritus of McKinsey & Company. During his tenure, he headed up McKinsey’s Electric Power and Natural Gas Practice from 1991 to 1999 and led the international consulting firm’s Nonprofit Practice from 2000 to 2004 — supporting nonprofit service providers, philanthropies, and public sector organizations across the firm’s network of 84 offices in 44 countries. He formerly held senior policy positions in the United States Departments of Interior and Energy.
NiSource Inc., an energy holding company, provides natural gas, electricity, and other products and services in the United States. It operates through three segments: Gas Distribution Operations, Columbia Pipeline Group Operations, and Electric Operations. The Gas Distribution Operations segment offers natural gas service and transportation to residential, commercial, and industrial customers. As of December 31, 2014, it owned and operated a total of 58,414 miles of pipelines and related facilities. This segment serves about 3.4 million customers in Ohio, Pennsylvania, Virginia, Kentucky, Maryland, Indiana, and Massachusetts.
In a mid-morning trade, AstraZeneca plc (ADR) (NYSE:AZN)‘s shares climbed 0.96%, to $67.64.
AstraZeneca (AZN) and MedImmune, the Company’s global biologics research and development arm, offered an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 1, 2015.
Commenting on the Company’s immuno-oncology combination data presented at ASCO, Chief Executive Officer, Pascal Soriot, said: “Immuno-oncology has continued to take center stage at ASCO this year, as we see more evidence of the significance of this approach for patients. At AstraZeneca we have been clear in our belief that combinations hold the key to transforming clinical practice for the patients not benefiting from the presently-accessible immunotherapies. The data presented on the combination of MEDI4736 and tremelimumab are truly exciting. As the frontrunner combination of two immuno-oncology molecules in non-small cell lung cancer, it is demonstrating promising clinical activity, in particular in the majority of patients who have low or no PD-L1 expression. With our longstanding expertise in developing small molecule medicines, counting olaparib and AZD9291, we are now also seeing the potential of combining these targeted medicines with immuno-oncology molecules to deliver efficacious and durable treatment to patients.”
Highlights of the update were:
- Data presented on MEDI4736, the Company’s anti-PD-L1 monoclonal antibody, as monotherapy in heavily pre-treated patients with non-small cell lung cancer (NSCLC) are encouraging and suggest that patients with PD-L1 positive tumors may have an improved overall response rate contrast to patients with PD-L1 negative tumors, highlighting the unmet medical need for the majority of tumors that are PD-L1 negative.
- MEDI4736 is demonstrating strong potential to combine with both immunotherapy and small molecules; AstraZeneca and MedImmune have an extensive development program underway across multiple tumor types and stages of disease, assessing the potential for immunotherapy to either replace or combine with traditional chemotherapy.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products comprise Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders.
Orbitz Worldwide, Inc. (NYSE:OWW), during its Wednesday’s current trading session gained 0.44% to $11.29.
Orbitz Worldwide, Inc. (OWW) declared that at its annual stockholders meeting recently in Chicago, stockholders approved the merger agreement providing for the acquisition of Orbitz Worldwide by Expedia, Inc. (EXPE). About 74 percent of the shares outstanding voted in favor of the transaction. More than 99 percent of the votes cast were in favor of the transaction.
Expedia, Inc. and Orbitz Worldwide declared their entry into the merger agreement on Feb. 12, 2015, whereby Expedia agreed to acquire all outstanding shares of Orbitz Worldwide at $12 per share. On March 25, the two companies declared that they had each received a request for additional information and documentary material (“second request”) from the U.S. Department of Justice (DOJ) as part of the agency’s regulatory review. The two companies continue to fully cooperate with the DOJ. The transaction also remains subject to additional customary closing conditions.
Orbitz Worldwide, Inc. operates as an online travel company worldwide. It uses technology that enables leisure and business travelers to research, plan, and book a range of travel products and services, counting hotels, flights, vacation packages, car rentals, rail tickets, cruises, travel insurance, destination, services and event tickets. It also provides various travel administration services; and private label travel solutions to a range of partners.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
